Sparsentan
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Proteinuria
Conditions
Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
Trial Timeline
Oct 7, 2025 → May 1, 2027
NCT ID
NCT07219121About Sparsentan
Sparsentan is a approved stage product being developed by Travere Therapeutics for Proteinuria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07219121. Target conditions include Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07219121 | Approved | Recruiting |
| NCT05856760 | Phase 2 | Completed |
| NCT05630612 | Phase 2 | Active |
| NCT04663204 | Phase 2 | Active |
Competing Products
6 competing products in Proteinuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zibotentan/Dapagliflozin + Dapagliflozin | AstraZeneca | Phase 2 | 52 |
| candesartan cilexetil | AstraZeneca | Phase 3 | 77 |
| Zibotentan/Dapagliflozin + Dapagliflozin | AstraZeneca | Phase 3 | 77 |
| valsartan | Novartis | Approved | 85 |
| Belatacept | Bristol Myers Squibb | Phase 2 | 51 |
| Losartan Potassium + Comparator: amlodipine besylate + Enalapril Maleate | Organon | Phase 3 | 72 |